{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:18:28Z","timestamp":1715386708005},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bulcan.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T16:31:26Z","timestamp":1711643486000},"page":"483-495","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Actualisation des donn\u00e9es sur le traitement n\u00e9oadjuvant total de l\u2019ad\u00e9nocarcinome du rectum"],"prefix":"10.1016","volume":"111","author":[{"given":"Maroussia","family":"Medioni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baptiste","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Parc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie H.","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bulcan.2024.02.004_bib0165","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3\u00a0trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.004_bib0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3\u00a0trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.004_bib0175","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","article-title":"Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2","volume":"28","author":"G\u00e9rard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.bulcan.2024.02.004_bib0180","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","article-title":"Clinical outcome of the ACCORD 12\/0405\u00a0PRODIGE 2\u00a0randomized trial in rectal cancer","volume":"30","author":"G\u00e9rard","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2024.02.004_bib0185","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.004_bib0190","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/annonc\/mdx351","article-title":"Late toxicities and clinical outcome at 5\u00a0years of the ACCORD 12\/0405-PRODIGE 02\u00a0trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer","volume":"28","author":"Azria","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.02.004_bib0195","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/annonc\/mdw062","article-title":"Long-course oxaliplatin-based preoperative chemoradiation versus 5 \u00d7 5Gy and consolidation chemotherapy for cT4\u00a0or fixed cT3\u00a0rectal cancer: results of a randomized phase III study","volume":"27","author":"Bujko","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.004_bib0200","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1470-2045(17)30086-4","article-title":"Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial","volume":"18","author":"Erlandsson","year":"2017","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.bulcan.2024.02.004_bib0205","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3\u00a0rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04","volume":"30","author":"Ngan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2024.02.004_bib0210","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdu147","article-title":"Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.02.004_bib0215","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdu560","article-title":"Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial","volume":"26","author":"Breugom","year":"2015","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.bulcan.2024.02.004_bib0220","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1200\/JCO.19.00016","article-title":"Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial","volume":"37","author":"Hong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.004_bib0225","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","article-title":"Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Breugom","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.004_bib0230","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(13)70599-0","article-title":"Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921\u00a0randomised study","volume":"15","author":"Bosset","year":"2014","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.bulcan.2024.02.004_bib0235","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.02.004_bib0240","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery \u2013 a five-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg [Internet]"},{"issue":"17_suppl","key":"10.1016\/j.bulcan.2024.02.004_bib0245","doi-asserted-by":"crossref","first-page":"LBA3504","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3504","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23\u00a0phase III trial, a UNICANCER GI trial","volume":"41","author":"Conroy","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.bulcan.2024.02.004_bib0250","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.radonc.2020.03.011","article-title":"Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - results of the international randomized RAPIDO-trial","volume":"147","author":"van der\u00a0Valk","year":"2020","journal-title":"Radiother Oncol"},{"issue":"31","key":"10.1016\/j.bulcan.2024.02.004_bib0255","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.2016.67.6049","article-title":"Effect of interval (7\u00a0or 11\u00a0weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6)","volume":"34","author":"Lefevre","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.bulcan.2024.02.004_bib0260","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.02.004_bib0265","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.annonc.2022.04.010","article-title":"Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial","volume":"33","author":"Jimenez-Fonseca","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.02.004_bib0270","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/codi.13381","article-title":"Oxaliplatin\/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Zhao","year":"2016","journal-title":"Colorectal Dis"},{"issue":"8","key":"10.1016\/j.bulcan.2024.02.004_bib0275","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.1999.17.8.2396","article-title":"Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01\u00a0randomized trial","volume":"17","author":"Francois","year":"1999","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.02.004_bib0280","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.004_bib0285","doi-asserted-by":"crossref","first-page":"e215445.26","DOI":"10.1001\/jamaoncol.2021.5445","article-title":"Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO\/ARO\/AIO-12\u00a0randomized clinical trial","volume":"8","author":"Fokas","year":"2022","journal-title":"JAMA Oncol"},{"issue":"0","key":"10.1016\/j.bulcan.2024.02.004_bib0290","first-page":"null","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"0","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2024.02.004_bib0295","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2468-1253(22)00392-2","article-title":"Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3\u00a0rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial","volume":"8","author":"Gerard","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10093","key":"10.1016\/j.bulcan.2024.02.004_bib0300","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0140-6736(17)31056-5","article-title":"Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3\u00a0trial","volume":"390","author":"Rullier","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.004_bib0305","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S2468-1253(20)30333-2","article-title":"Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study","volume":"6","author":"Bach","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bulcan.2024.02.004_bib0310","doi-asserted-by":"crossref","unstructured":"Bach S.P., de Wilt J.H.W., Peters F., Spindler K.L.G., Appelt A.L., Teo M., et al. STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer? J Clin Oncol 2022;40(16_suppl):3502.","DOI":"10.1200\/JCO.2022.40.16_suppl.3502"},{"issue":"12","key":"10.1016\/j.bulcan.2024.02.004_bib0315","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.ejca.2012.03.016","article-title":"What is the clinical benefit of preoperative chemoradiotherapy with 5FU\/leucovorin for T3-4\u00a0rectal cancer in a pooled analysis of EORTC 22921\u00a0and FFCD 9203\u00a0trials: surrogacy in question?","volume":"48","author":"Bonnetain","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.004_bib0160","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.radonc.2015.02.001","article-title":"Selection of appropriate end-points (pCR vs. 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer","volume":"114","author":"Valentini","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2024.02.004_bib316","article-title":"\u00ab\u202fCancer du rectum\u202f\u00bb","author":"Cotte","year":"2023","journal-title":"Th\u00e9saurus National de Canc\u00e9rologie Digestive"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124000845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124000845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:54:55Z","timestamp":1715320495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124000845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0007455124000845"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.02.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualisation des donn\u00e9es sur le traitement n\u00e9oadjuvant total de l\u2019ad\u00e9nocarcinome du rectum","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}